Abstract Details

Title The Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life in Chronic Migraine Patients Who Previously Used Topiramate

Topic Headache

Presentation(s) P1 - Poster Session 1 (5:30 PM-6:30 PM)

Poster/Presentation
Number 13-006

Objective

This study evaluated the effect of fremanezumab on health-related quality of life (HRQoL) using the Migraine-Specific Quality of Life (MSQoL) questionnaire in patients with chronic migraine (CM) who previously used topiramate.

Background

CM is characterized by frequent attacks, which adversely affect HRQoL. Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide, has been investigated for the preventive treatment of CM.

Design/Methods In this phase 3, multicenter, randomized, double-blind, parallel-group study, patients with CM were randomized 1:1:1 to receive subcutaneous fremanezumab quarterly (675 mg at baseline, and placebo at Weeks 4 and 8), fremanezumab monthly (675 mg at baseline and 225 mg at Weeks 4 and 8), or placebo at each time point over a 12-week treatment period. The MSQoL questionnaire (version 2.1) assessed the role function-restrictive (RR), role function-preventive (RP), and emotional function (EF) domains (range 0–100; higher scores indicate better HRQoL). MSQoL domains were analyzed using an analysis of covariance model (with treatment, gender, region, and baseline preventive medication use as fixed effects and baseline score and years since onset of migraines as covariates).

Results A total of 338/1121 patients with CM (fremanezumab quarterly: n=106; fremanezumab monthly: n=115; placebo: n=117) previously used topiramate and were included in this analysis. Fremanezumab treatment led to significantly greater improvements from baseline in MSQoL RR domain scores (quarterly [least-squares mean ± standard error]: 18.5±2.4, P=0.0026; monthly: 18.5±2.3, P=0.0022) compared with placebo (10.9±2.5) during the 12-week treatment period. Quarterly fremanezumab treatment led to significantly greater improvements from baseline in MSQoL RP domain scores (quarterly: 15.6±2.1, P=0.0248; monthly: 13.5±2.0, P=0.1834) compared with placebo (10.6±2.2) during the 12-week treatment period. Fremanezumab treatment did not have a significant effect on MSQoL EF domain scores.

Conclusions Fremanezumab improves certain MSQoL domain scores in patients with CM, regardless of previous use of topiramate.

Authors/Disclosures
Sanjay Gandhi, MD (Teva Pharmaceuticals) PRESENTER	Dr. Gandhi has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Richard B. Lipton, MD, FAAN (Albert Einstein College of Medicine)	Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clexio. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has or had stock in Biohaven.Dr. Lipton has or had stock in Manistee.Dr. Lipton has or had stock in Axon.Dr. Lipton has or had stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.
	No disclosure on file

��ɫ��

��ɫ��